Companies want patients to discover innovations before they reach the marketplace, so they’ll demand the therapies from physicians. It’s a process that starts long before launch.
Outreach in the early stages of development is paramount to an orphan drug’s marketability down the line. This often means initiating early engagement with associations, identifying obstacles to coverage way before a drug reaches the market, and securing coverage on formularies. These elements help companies hit the ground running when the drug is approved. [Full Article]